LithiXTM HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaquesNew clinical study to be presented at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco, CA, on October 27, 2025MILPITAS, Calif. , Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced key milestone and full market release of its LithiXTM Hertz Contact (HC) Intravascular Lithotripsy System (IVL), following the announcement of CE Mark approval earlier this year.The LithiX HC-IVL System is an advanced intravascular lithotripsy technology designed to optimize device expansion in calcified coronary artery blockages during an angioplasty procedure. Unlike energy-based systems with a more complex workflow requiring additional equipment, the LithiX device is a highly deliverable balloon-based system with integrated low-profile metallic hemispheres to create focal pressure amplification based on Hertz Contact Stress principle. The Hertz Contact Lithotripsy hemispheres work selectively on calcium within the target lesion, breaking apart and fragmenting the hardened plaque under ...Full story available on Benzinga.com